United States
Patient Instruction & Fitting Guides
Consumer
Search
Product search
Practitioner home > ECP Viewpoints℠ > Retention of Myopia Control with MiSight® 1 day Contact Lenses Post Treatment Supported by Peer-Reviewed Journal

Retention of Myopia Control with MiSight® 1 day Contact Lenses Post Treatment Supported by Peer-Reviewed Journal

May 02, 2025

A new, peer-reviewed paper in Optometry and Vision Science supports that myopia control gains with CooperVision’s MiSight® 1 day* dual-focus soft contact lenses are sustained after treatment, with eye growth aligning with that of untreated, age-matched populations.1 Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-Focus Soft Contact Lens (Chamberlain P, et al.)1 is now accessible via Open Access. 

The study followed subjects who had completed the six-year MiSight® 1 day clinical trial—both the cohort who wore MiSight® 1 day for all six years and the cohort that switched from the single vision to the MiSight® 1 day lens for the final three years—for an additional year following treatment cessation.1 The results indicated that there is no rebound effect with MiSight® 1 day contact lenses. After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the 12 months after treatment ceased.†2,3

“Eye Care Professionals (ECPs) have embraced the importance of myopia control in children, and we are starting to see this reflected in prescribing behaviour around the world,” said Paul Chamberlain, Senior Director of Research Programs at CooperVision and the paper’s lead author. “To turn the tide on childhood myopia, ECPs must be confident in an intervention that not only slows progression‡4 but makes long-term treatment worthwhile. MiSight® 1 day clearly demonstrates these benefits, allowing ECPs to prescribe with confidence for both immediate and lasting impact.” §◊4,5

The new paper also provides the most robust validation to date of this model for assessing long-term myopia control outcomes.1 Investigators applied the model to the study’s preliminary outcomes data, first shared in 2021, and subsequently found their initial conclusions to be highly accurate.

This publication adds to the previously published results of the study, joining the widely cited three-year and six-year results.4,5

For more information on the study and MiSight® 1 day, visit www.CooperVision.com.

17930
More Blog Posts
Related posts
Also of Interest:

*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight® 1 day.

‡Compared to a single vision 1 day lens.

§ActivControl® technology in MiSight® 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.

◊MiSight® 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.

References:

  1. Chamberlain, P, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. Optom and Vis Sci. 2025 Mar 25; ():10.1097/OPX.0000000000002244. 

  2. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.

  3. Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.

  4. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.

  5. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.

17930 05/25